BEDROCK 3D

BEDROCK 3D is a Dutch manufacturer of prime-quality 3D printing filaments, based in Emmen, the Netherlands. Founded in 2013 as Innofil3D, the company built over a decade of expertise in developing and producing filament for FFF/FDM 3D printing, including several years as part of BASF Forward AM. In 2025, it successfully relaunched its products as an independent, standalone brand: BEDROCK 3D.

With a team of around 30 people and an ISO 9001-certified production site, BEDROCK 3D develops and manufactures a broad portfolio of standard, advanced and flexible filaments. From PLA’s and rPET to TPU’s, PA and fibre-reinforced composites – supplying customers worldwide, from prosumers to industrial manufacturers, backed by technical support from in-house 3D printing expertise. 

BEDROCK 3D is also the material partner behind Insolution’s medical insoles, supplying the Foaming TPU used in their 3D-printed soles – an existing collaboration that led to 819 Capital Partners’ investment. Together with Insolution, BEDROCK 3D is part of NovioScan, bringing materials, software- & hardware technology and knowledge together to a complete 3D-printing solution for specific applications.

Our news

23 October, 2026

819 Capital Partners acquires CamperDays

Deventer, 23 October 2026 – 819 Capital Partners announces the acquisition of CamperDays through 819 Private Equity Fund I. Headquartered in Cologne, Germany, CamperDays is a leading international platform for campervan and motorhome rentals. The acquisition of CamperDays further strengthens 819 Capital Partners’ portfolio in the travel and leisure sector. CamperDays connects travellers with professional rental partners, providing access to more than 40,000 rental vehicles across over 1,000 locations in more than 35 countries. The...

Continue reading
16 September, 2026

Phosphoenix Secures €1.3 Million to Advance Visual Neuroprosthetic Technology

16 September 2026, Deventer, the Netherlands – Phosphoenix, a medical technology company developing a neuroprosthetic system for people with profound blindness, has completed a €1.3 million financing round from TTT MedTech Fund (managed by 819 Capital Partners), FIRST Fund (managed by BioGeneration Ventures), Innovatiefonds Noord-Holland and ROM InWest as new investor. The financing will support Phosphoenix’s preparations for its first-in-human (FIH) clinical study and the further development of its neurostimulation system. At the same time, the...

Continue reading